Enzyme-Linked Immunosorbent Assay Testing Market Size, Share, and Trends 2026 to 2035

The global enzyme-linked immunosorbent assay (ELISA) testing market is projected to grow from USD 2.57 billion in 2026 to USD 4.41 billion by 2035, registering a CAGR of 6.18%. Growth is driven by the rising prevalence of infectious diseases, cancer, and chronic disorders, increasing R&D activities in biotechnology and pharmaceuticals, expanding drug discovery and biomarker research, and growing demand for accurate, sensitive, and early disease diagnostics. North America dominated the market in 2024 due to strong research infrastructure, high healthcare spending, and increasing investments in diagnostic technologies, while Asia Pacific is expected to witness the fastest growth, supported by rising healthcare expenditure, improving healthcare infrastructure, increasing incidence of infectious diseases, and growing adoption of advanced diagnostic solutions.

Last Updated : 10 Sep 2026  |  Report Code : 1260  |  Category : Healthcare   |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Test Type

7.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Test Type

7.1.1. Sandwich ELISA

7.1.1.1. Market Revenue and Forecast

7.1.2. Indirect ELISA

7.1.2.1. Market Revenue and Forecast

7.1.3. Multiple and Portable ELISA

7.1.3.1. Market Revenue and Forecast

7.1.4. Competitive ELISA

7.1.4.1. Market Revenue and Forecast

7.1.5. Others

7.1.5.1. Market Revenue and Forecast

Chapter 8. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Application

8.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Application

8.1.1. Immunology

8.1.1.1. Market Revenue and Forecast

8.1.2. Inflammation

8.1.2.1. Market Revenue and Forecast

8.1.3. Infectious diseases

8.1.3.1. Market Revenue and Forecast

8.1.4. Cancer

8.1.4.1. Market Revenue and Forecast

8.1.5. Protein quantification

8.1.5.1. Market Revenue and Forecast

8.1.6. Other Applications

8.1.6.1. Market Revenue and Forecast

Chapter 9. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test

9.1.2. Market Revenue and Forecast, by Application

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test

9.1.3.2. Market Revenue and Forecast, by Application

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test

9.1.4.2. Market Revenue and Forecast, by Application

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test

9.2.2. Market Revenue and Forecast, by Application

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test

9.2.3.2. Market Revenue and Forecast, by Application

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test

9.2.4.2. Market Revenue and Forecast, by Application

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test

9.2.5.2. Market Revenue and Forecast, by Application

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test

9.2.6.2. Market Revenue and Forecast, by Application

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test

9.3.2. Market Revenue and Forecast, by Application

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test

9.3.3.2. Market Revenue and Forecast, by Application

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test

9.3.4.2. Market Revenue and Forecast, by Application

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test

9.3.5.2. Market Revenue and Forecast, by Application

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test

9.3.6.2. Market Revenue and Forecast, by Application

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test

9.4.2. Market Revenue and Forecast, by Application

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test

9.4.3.2. Market Revenue and Forecast, by Application

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test

9.4.4.2. Market Revenue and Forecast, by Application

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test

9.4.5.2. Market Revenue and Forecast, by Application

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test

9.4.6.2. Market Revenue and Forecast, by Application

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test

9.5.2. Market Revenue and Forecast, by Application

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test

9.5.3.2. Market Revenue and Forecast, by Application

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test

9.5.4.2. Market Revenue and Forecast, by Application

Chapter 10. Company Profiles

10.1. Thermo Fisher Scientific, Inc.

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. American Laboratory Products Company (ALPCO)

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Bio-Rad Laboratories, Inc.

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. BD

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. BioMérieux SA

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Ortho Clinical Diagnostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. R&D Systems, Inc.

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. ZEUS Scientific, Inc.

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The global enzyme-linked immunosorbent assay (ELISA) testing market size was valued at USD 2.57 billion in 2026 and is predicted to reach USD 4.41 billion by the end of 2035, representing impressive CAGR of 6.18% during the forecast period 2026 to 2035.

Answer : The global enzyme-linked immunosorbent assay (ELISA) testing market is representing impressive CAGR of 6.32% during the forecast period 2026 to 2035.

Answer : Factors such as growingincidence of infectious disorders such as hepatitis, dengue, and AIDS, increasing prevalence of neurological disorders, growing geriatric population, high research and development expenditure of major players, growing per capita healthcare spending, growing incidence of non-communicable diseases, and emergence of cost-effective technologies are driving the growth of enzyme-linked immunosorbent assay (ELISA) testingmarket.Increasing focus on laboratory automation and growing R&D activities in monoclonal antibodies (mABs) and biomarkers are further propelling the enzyme-linked immunosorbent assay (ELISA) testingmarket expansion across the globe. The most important advantage of using ELISA is its specificity and sensitivity with antibodies that are customized for a spec

Answer : In 2024, North America dominated the global market with a market share of more than 42%.

Answer : The Asia Pacific region is projected to lead with highest CAGR of about 7.8% in the estimate duration majorly because of high frequency of infectious ailments.African, Latin American, and Middle Eastern region will display perceptible progress.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client